ous tissues (5); he also reported the presence of CEA-related substances, which can cross-react with CEA antibody, both in normal and in pathological sera. We therefore supposethat QC samples prepared from different materials may be heterogeneous with respect to CEA and (or) nonspecific crossreacting substances, and may have been measured in different ways by the kits considered.
Monoclonai Antibody is Specific for Salivary Amylase

To the Editor:
Contrary to a statement published recently in this journal (1), our monoclonal antibody against salivary amylase does not react with the pancreatic isoenzyme. Redondo (1), describing the inhibition of salivary-type amylase by inhibitor from wheat, states that "such inhibition is not completely selective,
however, and not all the salivary-type activity disappears, nor does the pancreatic-type activity remain unaffected, after the action of the inhibitor." Following this accurate statement, the author states, "This is also what happens. . . in the more recently described immunological methods." This statement is incorrect for the referenced method (2) developed in our laboratory. As we reported (2), we could find no evidence of cross-reactivity of our anti- Glucose Test "Carryover" Affects Drug Assays in the IL "Monarch"
In response to the Letter by Overfield (Clin Chem 1987;33:743) concerning drug assays on the IL Monarch, the problem had been resolved by the manufacturer by the time of publication.
Dr. Overfield reported that the change in absorbance (M) was erroneously increased for a specimen analyzed for a drug after the same or another specimen had been analyzed for glucose. He concluded that some glucose-6-phosphate dehydrogenase (G6PDH; EC 1.1.1.49) in the glucose reagent was being retained in the pipetting system of the Monarch and was being delivered with the EMIT reagent into the rotor.
When we reviewed Dr. Overfield's data and tried to duplicate the phenomenon in several Monarch instruments, we could not obtain significant "carryover" of IL Glucose reagent into EMIT reagent to affect the results for the first sample. However, the phenomenon was real in the Wake Medical Center data. After further investigation, we identified a lot of pipettor arms that had not been properly processed. These pipettor arms contain stainless-steel tubing coils that serve as sample/diluent heat exchangers to bring sample and reagent to the temperature of analysis before they are dispensed in the Monarch rotor. These stainless-steel tubes had not been properly passivated, i.e., treated with nitric acid to remove unbound iron. 
Factors Affecting Urinary Screens for Acetaminophen
To the Editor:
Having read the article by Ray et al. (Clin Chem 1987; 33:718) on the alkaline o-cresol test for acetaminophen in urine, we should like to point out two factors that, in our experience, are critical: adequate hydrolysis and the final dilution for color development. We normally integrate the test for acetaminophen into our preparation of a urine for detection of benzodiazepine as follows: Add about 6 mL of urine and 1 mL of concentrated HC1 to a narrow 100 x 10 mm test tube and place this in a heating block, to heat the urine to about 60-65 #{176}C for 30 mm. Then decant the urine into a second tube for extraction of benzodiazepines, leaving not more than 50 L in the narrow tube. Add about 1 mL of o-cresol to the narrow tube, then fill it with 4 mol/L ammonia solution and mix.
If acetaminophen ispresent,a blue color begins to appear within 1 or 2 s and steadily darkens over the next few minutes. If allowed to stand for hours an initially colorless solution always takes on a slight blue tinge. The considerable dilution is important and appears to govern the rate of color development. Leaving more hydrolyzed urine in the tube or using a lesser dilution appears to inhibit color development.
Over a period of 10 years, we have not had cause to suspect false negatives. In fact, we find we can detect acetaminophen in the urine of cases of overdose with delayed admission, when the concentration in blood has already fallen to low values. 
In a recent paper, Parker et al.
(1) described the quantitative determination of urinary catecholamines, metanephrines, vanillylmandelic acid (VMA), and 5-hydroxyindoleacetic acid (5HIAA) by liquid chromatography with electrochemical detection. After extraction from urine, each of these analytes was measured by one of three coluxnn-chromatographic techniques, under uniform conditions. These authors claim to have used a Waters (2) 5-pm (particle size) C18 NovaPak column with a mobile phase of (per liter) 0.05 mol of monochioroacetic acid, 0.05 mol of citric acid, 80 mL of acetonitrile, 0.45 mL of diethylamine, and 0.15 g of sodium octyl sulfate as an ion-pairing agent.
Attempting to eliminate the need for re-equilibration of a chromatographic system with separate mobile phases to assay both the free catecholainines and the metabolites VMA, 5HIAA, and homovanillic acid (HVA), we purchased a NovaPak C18 150 x 3.9 mm stainless-steel column from Waters (2). Using the mobile phase and conditions given by Parker et al. (1), namely a flow rate of 0.8 mL/min at room temperature, with a potential of 800 mV vs an Ag/AgC1 reference electrode, and operating with a Waters Model 510 pump and a Waters Model 460 electrochemical detector, we were unable to reproduce the retention times they reported.
Together with 3,4-dihydroxyphenylacetic acid, HVA is the principal metabolite of dopamine and is excreted in the urine in increased amounts in neuroblastoma (3); it is easily measured under the described conditions. Below, we compare the retention times we obtained for aqueous preparations of the catecholamine-related metabolites with those of Parker et al.
(1). The 5HIAA peak was not separated from that of 5-hydroxyindole carboxylic acid (5HICA), the internal standard:
RetentIontIme, mln
Ref. I
A similar comparison of retention times for the free catecholamines is shown here:
Resolution of the catecholamines was inadequate; norepinephrine coeluted with epinephrine and the capacity of the column was insufficient, such that all the peaks had been eluted within 3.2 mm. We modified the concentrations of acetonitrile and the ion-pairing agent in the mobile phase, and used di-nbutylamine in place of diethylamine.
Although decreasing the acetonitrile concentration greatly improved the resolution, the most limiting factor affecting the separation was the concentration of di-n-butylamine (Table 1) . Altering the concentration of the ionpairing agent had little effect, although resolution was better with the octyl-rather than the heptyl-derivative. Both the catecholanunes and their related metabolites could be separated by including 0.3 mL of di-nbutylamine per liter. However, excluding di-n.butylainine from the mobile phase gave the best resolution of the catecholaniines; analysis of the metabolites required using 1.0 mL of di-nbutylamine per liter to shorten the retention times.
Parker et al.
(1) did not specify the Retention tim., mm
VMA
5HIAA
5IIICA
HVA
Catecholamine-related metabolites
